Novel--and "neu"--therapeutic possibilities for heart failure.

dverse effects of pharmacotherapeutics in patients rarely ead to novel therapies in animal models of disease. In this ssue of the Journal, however, Liu et al. (1) provide a emarkable case of such “bedside-to-bench” research: they emonstrate that neuregulin-1 therapy substantially mitiates heart failure in infarct-, viral-, anthracycline-, nd pacing-induced models that employ rodents and dogs— xperimental proofs of concept critical for launching human tudies. The discovery by Liu et al. (1) derived, in part, from he observation that trastuzumab (Herceptin) therapy for reast cancer engenders cardiomyopathy (2). Why does